Resonant Down 70%… Could CorMedix Inc. (CRMD) Be Next?

Last February we warned about Resonant and since then the stock has fallen over 70%. We believe Coremedix has many of the same attributes that alarmed us about RESN. We believe CRMD is wildly overvalued, is poised for a big drop and suggest that investors avoid or consider shorting CRMD. CorMedix has a market capitalization of $400 million, its stock is up 370% year to date, its trading at 2,000x 2014 revenue (yes 2,000 times), it has a going concern, it needs to raise capital, it recently filed an equity offering, it faces significant regulatory and commercial challenges, it has…